The iShares MSCI USA Quality Factor ETF (QUAL) invests in U.S. stocks with high return on equity, earnings stability, and low debt, focusing heavily on technology (over 40%) but maintaining broad diversification across 123 holdings. With a forward price-to-earnings ratio of 22.2, return on equity above 30%, and a projected internal rate of return of 11.8%, the fund appears moderately undervalued, offering a strong equity risk premium. Analysts view QUAL as a buy-and-hold investment, suggesting that market dips driven by macroeconomic factors could present good buying opportunities due to its margin of safety against rising yields and earnings risks.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
